Peak Retirement Planning Inc. Takes $917,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Peak Retirement Planning Inc. purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 10,238 shares of the medical equipment provider’s stock, valued at approximately $917,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Woodline Partners LP grew its position in Lantheus by 2.7% in the fourth quarter. Woodline Partners LP now owns 88,018 shares of the medical equipment provider’s stock worth $7,874,000 after acquiring an additional 2,340 shares in the last quarter. State of Wyoming lifted its stake in shares of Lantheus by 662.2% in the 4th quarter. State of Wyoming now owns 4,558 shares of the medical equipment provider’s stock valued at $408,000 after purchasing an additional 3,960 shares during the last quarter. Tema Etfs LLC bought a new stake in Lantheus in the fourth quarter worth $712,000. Sarissa Capital Management LP increased its position in Lantheus by 142.3% during the fourth quarter. Sarissa Capital Management LP now owns 63,000 shares of the medical equipment provider’s stock worth $5,636,000 after buying an additional 37,000 shares during the last quarter. Finally, Select Equity Group L.P. bought a new position in Lantheus during the fourth quarter valued at about $903,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

LNTH has been the subject of a number of analyst reports. Wall Street Zen raised Lantheus from a “hold” rating to a “buy” rating in a research report on Thursday, May 8th. Truist Financial reduced their target price on Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a report on Thursday, May 8th. Finally, B. Riley lowered their price target on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a report on Friday, March 21st. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $132.67.

Insider Activity at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock worth $6,016,046 in the last ninety days. 1.50% of the stock is currently owned by insiders.

Lantheus Stock Performance

NASDAQ LNTH opened at $73.86 on Friday. The stock has a 50-day simple moving average of $94.56 and a 200 day simple moving average of $92.07. Lantheus Holdings, Inc. has a twelve month low of $73.11 and a twelve month high of $126.89. The stock has a market capitalization of $5.11 billion, a PE ratio of 12.29 and a beta of 0.23.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. During the same quarter last year, the firm earned $1.69 earnings per share. The firm’s quarterly revenue was up .8% compared to the same quarter last year. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.